Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Posts Earnings Results, Beats Estimates By $0.12 EPS

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) announced its quarterly earnings data on Wednesday. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.12, FiscalAI reports.

Damora Therapeutics, Inc. Common Stock Stock Up 3.9%

Shares of Damora Therapeutics, Inc. Common Stock stock traded up $0.86 on Wednesday, hitting $22.94. The company’s stock had a trading volume of 736,739 shares, compared to its average volume of 432,015. Damora Therapeutics, Inc. Common Stock has a 52-week low of $4.95 and a 52-week high of $38.33. The firm has a fifty day moving average price of $23.18 and a 200-day moving average price of $25.74. The company has a market capitalization of $1.42 billion, a P/E ratio of -6.81 and a beta of 1.52.

Insider Buying and Selling

In other Damora Therapeutics, Inc. Common Stock news, CEO Jennifer Jarrett bought 12,500 shares of the company’s stock in a transaction on Friday, September 25th. The stock was purchased at an average cost of $20.23 per share, for a total transaction of $252,875.00. Following the acquisition, the chief executive officer owned 512,500 shares of the company’s stock, valued at $10,367,875. The trade was a 2.50% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.40% of the company’s stock.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Several institutional investors and hedge funds have recently modified their holdings of the business. Arizona State Retirement System purchased a new position in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $260,000. Squarepoint Ops LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at approximately $303,000. Seven Fleet Capital Management LP purchased a new stake in Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at approximately $7,398,000. Finally, Braidwell LP acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 2nd quarter valued at $42,146,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

Analysts Set New Price Targets

DMRA has been the topic of several recent analyst reports. Guggenheim upped their target price on shares of Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, September 25th. TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. Jefferies Financial Group assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They set a “buy” rating and a $50.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $46.50.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.